Pina-Sanchez, M. (Manuel)

Filtering

2023 - 20242

Settings

Author search.filters.isAuthorOfPublication.41176154-3bbb-408d-8895-eac9f9cd370c

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses.
    (Frontiers, 2023) Moreno-Galarraga, L. (Laura); Martin-Navarro, L. (Loreto); González-Aseguinolaza, G. (Gloria); Muñoz-Rodríguez, N. (Natalia); Pineda-Lucena, A. (Antonio); Olagüe, C. (Cristina); Pina-Sanchez, M. (Manuel); Camps, G. (Gracian); Rua, M. (Marta); Smerdou, C. (Cristian); Pozo, J.L. (José Luis) del; Pozuelo, M. (Marta); Zuaznabar, J. (Jon); Rodriguez, J.A. (José Antonio); Carmona-Torre, F. (Francisco de A.); Fernandez-Montero, A. (Alejandro); Zazpe, J. (Jon); Reina, G. (Gabriel); Kolenda, J. (Jack); Marchese, F.P. (Francesco P.); Quiroga, J. (Jorge); Martínez-Fernández, M. (Maria); Argemí, J. (Josepmaria); Pastrana, M. (Marta); Maestro, S. (Sheila)
    Background: The main objective was to evaluate the efficacy of intranasal photodynamic therapy (PDT) in SARS-CoV-2 mildly symptomatic carriers on decreasing the infectivity period. SARS-CoV-2-specific immune-stimulating effects and safety were also analysed. Methods: We performed a randomized, placebo-controlled, clinical trial in a tertiary hospital (NCT05184205). Patients with a positive SARS-CoV-2 PCR in the last 48 hours were recruited and aleatorily assigned to PDT or placebo. Patients with pneumonia were excluded. Participants and investigators were masked to group assignment. The primary outcome was the reduction in in vitro infectivity of nasopharyngeal samples at days 3 and 7. Additional outcomes included safety assessment and quantification of humoral and T-cell immune-responses. Findings: Patients were recruited between December 2021 and February 2022. Most were previously healthy adults vaccinated against COVID-19 and most carried Omicron variant. 38 patients were assigned to placebo and 37 to PDT. Intranasal PDT reduced infectivity at day 3 post-treatment when compared to placebo with a b-coefficient of -812.2 (CI95%= -478660 – -1.3, p<0.05) infectivity arbitrary units. The probability of becoming PCR negative (ct>34) at day 7 was higher on the PDT-group, with an OR of 0.15 (CI95%=0.04-0.58). There was a decay in anti-Spike titre and specific SARS-CoV-2 T cell immunity in the placebo group 10 and 20 weeks after infection, but not in the PDT-group. No serious adverse events were reported. Interpretation: Intranasal-PDT is safe in pauci-symptomatic COVID-19 patients, it reduces SARS-CoV-2 infectivity and decelerates the decline SARS-CoV-2 specific immune-responses.
  • Thumbnail Image
    High pre‐Delta and early‐Omicron SARS‐CoV‐2 seroprevalence detected in dried blood samples from Kinshasa (D.R. Congo)
    (Wiley, 2024) Carlos-Chillerón, S. (Silvia); Burgueño, E. (Eduardo); Holguín, Á. (África); Mbikayi, S. (Samclide); Pina-Sanchez, M. (Manuel); Martínez-de-Aguirre, P. (Paula); Chiva, L. (Luis); Reina, G. (Gabriel); Mbamba-Baluanda, C.T. (Cèline Tendobi)
    Studies on the impact of the COVID‐19 pandemic in sub‐Saharan Africa have yielded varying results, although authors universally agree the real burden surpasses reported cases. The primary objective of this study was to determine SARS‐CoV‐2 seroprevalence among patients attending Monkole Hospital in Kinshasa (D.R. Congo). The secondary objective was to evaluate the analytic performance of two chemiluminescence platforms: Elecsys® (Roche) and VirClia® (Vircell) on dried blood spot samples (DBS). The study population (N = 373) was recruited in two stages: a mid‐2021 blood donor cohort (15.5% women) and a mid‐2022 women cohort. Crude global seroprevalence was 61% (53.9%–67.8%) pre‐Delta in 2021 and 90.2% (84.7%–94.2%) post‐Omicron in 2022. Anti‐spike (S) antibody levels significantly increased from 53.1 (31.8–131.3) U/mL in 2021 to 436.5 (219.3–950.5) U/mL in 2022 and were significantly higher above 45 years old in the 2022 population. Both platforms showed good analytic performance on DBS samples: sensitivity was 96.8% for IgG (antiN/S) (93.9%–98.5%) and 96.0% (93.0%–98.0%) for anti‐S quantification. These results provide additional support for the notion that exposure to SARS‐CoV‐2 is more widespread than indicated by case‐based surveillance and will be able to guide the pandemic response and strategy moving forward. Likewise, this study contributes evidence to the reliability of DBS as a tool for serological testing and diagnosis in resource‐limited settings.